Real World Study of VIEKIRAX (ombitasvir/paritaprevir/ritonavir) and EXVIERA (dasabuvir) With Or Without Ribavirin In Patients With Chronic Hepatitis C Virus Infection.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 25 Sep 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
Indications Hepatitis C
Focus Adverse reactions; Therapeutic Use
Acronyms AMBER

14 Apr 2018 According to results presented at The International Liver Congress 2018, this first real world experience study was carried-out in 2014-2015.
14 Apr 2018 Results (n=202) of an analysis of two years follow-up focusing on risk of hepatocellur carcinoma development, presented at The International Liver Congress 2018.
24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com